Estados financieros detallados de Nurix Therapeutics, Inc. (NRIX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Nurix Therapeutics, Inc. registró ingresos de $84.0M en el último ejercicio fiscal, con un CAGR de 5 años del 36.3%.
Márgenes de los últimos 12 meses: margen bruto -165.5%, margen operativo -9.8%, margen neto -9.3%.
Al precio actual de $24.83, NRIX presenta beneficios negativos (P/E no significativo) y un ROE del -76.09%. La capitalización bursátil es de $2.6B.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $37.4M | $31.1M | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Coste de Ventas | $40.5M | $45.0M | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | $18.9M |
| Beneficio Bruto | -$3.1M | -$13.9M | -$48.7M | -$86.7M | -$145.9M | -$112.2M | -$167.1M | $65.1M |
| I+D | $40.5M | $45.0M | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | $308.2M |
| Generales y Administrativos | $6.7M | $8.3M | $16.3M | $31.2M | $38.0M | $42.9M | $45.9M | $52.7M |
| Gastos Operativos | $6.7M | $8.3M | $16.3M | $31.2M | $38.0M | $42.9M | $45.9M | $350.8M |
| Beneficio Operativo | -$9.7M | -$22.2M | -$65.0M | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| EBITDA | -$6.8M | -$19.9M | -$62.8M | -$115.1M | -$176.2M | -$137.8M | -$185.3M | -$244.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$8.9M | -$21.5M | -$63.8M | -$117.1M | -$180.4M | -$143.9M | -$193.3M | -$263.7M |
| Impuestos | $507000 | $239000 | -$20.5M | $131000 | 0 | 0 | $270000 | $760000 |
| Beneficio Neto | -$9.4M | -$21.7M | -$43.2M | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| BPA | $-0.59 | $-0.56 | $-2.76 | $-2.73 | $-3.71 | $-2.65 | $-2.88 | $-3.05 |
| BPA Diluido | $-0.59 | $-0.56 | $-2.76 | $-2.73 | $-3.71 | $-2.65 | $-2.88 | $-3.05 |
| Acciones en Circulación (Diluidas) | $16.1M | $38.8M | $15.7M | $42.9M | $48.6M | $54.3M | $67.1M | $86.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $7.9M | $13.6M | $6.3M | $9.0M |
| Beneficio Bruto | $2.9M | $8.9M | -$77.9M | $5.2M |
| Beneficio Operativo | -$91.4M | -$83.1M | -$92.5M | -$94.2M |
| EBITDA | -$81.4M | -$69.0M | -$83.4M | -$86.0M |
| Beneficio Neto | -$86.4M | -$78.2M | -$87.2M | -$89.5M |
| BPA | $-1.03 | $-0.82 | $-0.79 | $-0.81 |
| BPA Diluido | $-1.03 | $-0.82 | $-0.79 | $-0.81 |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $25.6M | $34.8M | $119.4M | $80.5M | $64.5M | $54.6M | $110.0M | $247.0M |
| Inversiones a Corto | $13.4M | $2.9M | $161.8M | $215.2M | $244.7M | $233.3M | $499.6M | $346.0M |
| Cuentas por Cobrar | 0 | 0 | $11.3M | $6.2M | $1.1M | $800000 | $1.5M | 0 |
| Inventario | 0 | 0 | 0 | 0 | -$1.1M | 0 | 0 | 0 |
| Activos Corrientes | $40.7M | $39.4M | $298.4M | $311.1M | $318.4M | $295.5M | $619.4M | $606.8M |
| Inmovilizado Material | $4.4M | $3.9M | $6.7M | $25.3M | $29.5M | $48.0M | $45.9M | $73.0M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $45.4M | $44.0M | $396.3M | $476.8M | $416.8M | $355.6M | $669.3M | $688.1M |
| Cuentas por Pagar | $1.3M | $1.6M | $3.4M | $6.7M | $5.1M | $6.4M | $11.5M | $11.2M |
| Deuda a Corto | 0 | 0 | 0 | $3.8M | $5.5M | $7.5M | 0 | 0 |
| Pasivos Corrientes | $32.8M | $16.1M | $44.5M | $66.3M | $70.7M | $87.0M | $95.9M | $86.5M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $34.0M | $53.6M | $106.1M | $134.5M | $113.1M | $155.1M | $142.3M | $149.4M |
| Reservas | -$38.8M | -$60.5M | -$103.7M | -$220.9M | -$401.3M | -$545.2M | -$738.8M | -$1.00B |
| Patrimonio Neto | -$36.8M | -$57.7M | $290.3M | $342.3M | $303.7M | $200.5M | $527.0M | $538.7M |
| Deuda Total | 0 | 0 | 0 | $13.0M | $12.0M | $30.6M | $28.3M | $55.7M |
| Deuda Neta | -$39.0M | -$37.7M | -$281.1M | -$282.7M | -$297.2M | -$257.3M | -$581.3M | -$537.2M |
| Capital Circulante | $7.8M | $23.2M | $253.9M | $244.9M | $247.8M | $208.5M | $523.5M | $520.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $78.4M | $247.0M | $71.2M | $67.7M |
| Activos Totales | $522.5M | $688.1M | $636.1M | $535.5M |
| Pasivos Totales | $150.2M | $149.4M | $155.2M | $132.9M |
| Patrimonio Neto | $372.3M | $538.7M | $480.9M | $402.6M |
| Deuda Total | $56.5M | $55.7M | $58.7M | $58.1M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$9.4M | -$21.7M | -$43.2M | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| Amortizaciones | $3.0M | $2.4M | $2.2M | $6.1M | $10.8M | $13.7M | $16.4M | $18.9M |
| Compensación en Acciones | $431000 | $510000 | $4.3M | $15.8M | $28.1M | $33.7M | $33.9M | $38.0M |
| Cambio en Capital Circulante | -$25.3M | $19.5M | $36.4M | $9.1M | -$19.0M | $20.1M | -$18.4M | -$31.6M |
| Flujo de Caja Operativo | -$31.7M | $601000 | -$80000 | -$84.4M | -$159.8M | -$81.4M | -$172.6M | -$249.5M |
| Inversiones (CapEx) | -$1.6M | -$1.7M | -$4.6M | -$5.7M | -$12.2M | -$8.4M | -$9.3M | -$14.0M |
| Adquisiciones | $6000 | -$10.1M | $249.9M | $102.6M | -$39.4M | 0 | 0 | 0 |
| Recompra de Acciones | -$2000 | -$16000 | -$7000 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$33.3M | -$1.1M | -$4.6M | -$90.0M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$57.4M | -$67.8M | -$71.9M | -$96.6M |
| Inversiones (CapEx) | -$2.7M | -$5.1M | -$1.0M | -$1.9M |
| Flujo de Caja Libre | -$60.1M | -$73.0M | -$73.0M | -$98.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $9.8M | $9.1M | $9.4M | $11.4M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | -16.9% | -42.7% | +66.9% | +29.8% | +99.3% | -29.1% | +54.0% |
| Crecimiento Beneficio Neto (anual) | | -130.2% | -99.3% | -171.0% | -53.9% | +20.2% | -34.5% | -36.6% |
| Crecimiento BPA (anual) | | +5.1% | -392.9% | +1.1% | -35.9% | +28.6% | -8.7% | -5.9% |
| Cambio en Acciones (anual) | | +141.2% | -59.7% | +173.7% | +13.3% | +11.8% | +23.5% | +29.1% |
| Crecimiento FCF (anual) | | +96.8% | -341.2% | -1843.1% | -91.1% | +47.8% | -102.6% | -44.9% |
| Margen Bruto | -8.2% | -44.7% | -273.1% | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| Margen Operativo | -26.0% | -71.5% | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Margen EBITDA | -18.0% | -63.9% | -352.4% | -386.8% | -456.2% | -179.0% | -339.7% | -291.5% |
| Margen Neto | -25.2% | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| Margen FCF | -88.8% | -3.4% | -26.0% | -302.6% | -445.4% | -116.6% | -333.4% | -313.7% |
| Tasa Impositiva Efectiva | -5.7% | -1.1% | 32.2% | -0.1% | -0.0% | -0.0% | -0.1% | -0.3% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-2.07 | $-0.03 | $-0.30 | $-2.10 | $-3.54 | $-1.65 | $-2.71 | $-3.04 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $16.1M | $38.8M | $15.7M | $42.9M | $48.6M | $54.3M | $67.1M | $86.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -76.09% |
| Rentabilidad sobre capital invertido | -77.32% |
| Rentabilidad sobre activos | -63.74% |
| Margen bruto | -165.51% |
| Margen operativo | -982.37% |
| Margen neto | -928.44% |
Salud financiera
| Deuda / Patrimonio | 0.14 |
| Ratio corriente | 6.34 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.50 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -32.22 | -33.95 | -15.44 | -10.56 | -3.34 | -2.35 | -7.68 | -5.54 |
| P/VC | -8.31 | -12.79 | 2.30 | 3.61 | 1.98 | 1.69 | 2.82 | 2.72 |
| P/V | 8.18 | 23.73 | 37.49 | 41.55 | 15.59 | 4.39 | 27.21 | 17.45 |
| Margen Bruto | -8.2% | -44.7% | -273.1% | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| Margen Operativo | -26.0% | -71.5% | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Margen Neto | -25.2% | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |